Recent news highlights InspireMD’s Q4 revenue growth, guidance for 65% revenue growth in 2026, continued net losses, and progress in U.S. commercialization including the launch of CGuard Prime and appointment of a new Chief Medical Officer.

• InspireMD reported Q4 revenue growth and provided guidance for 65% revenue growth in 2026, with the stock rising following the announcement [N1].
• The company reported a Q4 loss but exceeded revenue expectations, reflecting ongoing investment in commercialization [N3].
• InspireMD launched the CGuard Prime Carotid Stent System in the U.S. in July 2025 following FDA approval [N7].
• The company appointed Peter Soukas as Chief Medical Officer in November 2025 to support clinical and commercial efforts [N7].
• Enrollment in the CGUARDIANS II pivotal study for CGuard Prime was completed in Q1 2026, supporting clinical validation [S1].

InspireMD’s clinical evidence, including results from the C-GUARDIANS pivotal trial and CREST-2 study, supports the safety and efficacy of its CGuard stents, potentially driving adoption of a stent-first approach in carotid revascularization. The expanded CMS coverage for carotid stenting and TCAR procedures broadens the U.S. addressable market. The company’s recent FDA PMA approval and U.S. commercial launch of CGuard Prime, along with enrollment completion in pivotal studies, mark key execution milestones. Expansion of manufacturing capacity and international market presence could support revenue growth. The development of SwitchGuard NPS and new clinical indications may further enhance the product portfolio.

InspireMD faces substantial risks including its history of net losses and recurring negative cash flows, with management expressing substantial doubt about its ability to continue as a going concern. The company has limited experience in U.S. commercialization and must successfully build sales, marketing, and distribution capabilities. Market acceptance of CGuard Prime is uncertain and may be hindered by physician reluctance, reimbursement challenges, and competition from larger medical device companies. Geopolitical instability in Israel, where manufacturing is based, poses operational risks. The company requires additional capital to fund growth and commercialization efforts, and failure to secure financing could adversely impact operations.

InspireMD’s moat is based on its proprietary MicroNet mesh technology integrated into its CGuard stent systems, which provide embolic protection during and after carotid artery stenting. Clinical trial data demonstrate low adverse event rates and potential advantages over conventional stents and surgical alternatives. The company holds CE Mark and FDA PMA approvals, supported by ongoing pivotal studies. Its intellectual property portfolio protects the MicroNet platform globally. The combination of clinical differentiation, regulatory approvals, and expanding commercial infrastructure supports competitive positioning in a specialized medical device market.

• Commercialization Risks: Limited experience in U.S. sales and marketing; challenges in recruiting and retaining personnel; potential failure to achieve market acceptance and sufficient reimbursement.
• Financial Risks: History of net losses and negative cash flows; substantial doubt about going concern; need to raise additional capital which may dilute shareholders.
• Geopolitical Risks: Operations and manufacturing in Israel subject to regional conflicts and political instability, which could disrupt supply chains and business operations.
• Competitive Risks: Competition from larger, better-capitalized medical device companies with broader product lines and established customer relationships.
• Regulatory and Reimbursement Risks: Dependence on regulatory approvals and favorable reimbursement policies; changes in healthcare laws and pricing pressures could impact demand and profitability.

• InspireMD, Inc. is a medical device company specializing in development and commercialization of products for carotid artery disease and other vascular conditions.
• The company’s product portfolio includes two commercial products based on proprietary CGuard carotid stent technology designed to provide embolic protection during and after stenting procedures.
• The first product, CGuard Carotid Embolic Prevention System (CGuard EPS), integrates a self-expanding nitinol stent with a MicroNet mesh sleeve and is marketed in over 30 countries outside the U.S. through distributors.
• CGuard EPS received CE Mark recertification under EU MDR in January 2024.
• The second product, CGuard Prime Carotid Stent System, uses the same stent and MicroNet mesh with a differentiated deployment mechanism, received FDA PMA approval on June 23, 2025, and MDR CE Mark approval on June 12, 2025.
• CGuard Prime is marketed exclusively in the U.S. through a direct salesforce following its commercial launch in July 2025.
• The company completed enrollment in the CGUARDIANS II pivotal study of CGuard Prime for TCAR procedures in Q1 2026.
• CMS issued a final National Coverage Determination in October 2023 expanding coverage for carotid artery stenting and TCAR procedures to include asymptomatic and standard risk patients, expanding the U.S. addressable market.
• CREST-2 study results released in November 2025 showed carotid artery stenting combined with medical therapy reduces stroke risk compared to medical management alone in severe asymptomatic carotid stenosis.
• InspireMD’s business strategy focuses on establishing CGuard as a global leader in carotid revascularization, driving adoption of a stent-first approach, leveraging clinical differentiation, expanding U.S. commercial infrastructure, broadening product portfolio, growing international presence, and protecting intellectual property.
• The company’s addressable market for CGuard EPS, CGuard Prime, and SwitchGuard NPS is estimated at approximately $1.3 billion assuming full penetration of intervention caseload, with a total available market of about $9.3 billion including all diagnosed patients.
• SwitchGuard NPS is a neuroprotection system under development to provide flow reversal during TCAR procedures; the company received FDA IDE approval in June 2025 to initiate the CGUARDIANS III clinical trial.
• The company is pursuing new clinical applications including treatment of acute ischemic stroke with tandem lesions, currently studied in an early feasibility study with Jacobs Institute.
• Manufacturing is performed in Israel with assembly of stents and MicroNet mesh; the company is transferring production of CGuard Prime finished goods to a contract manufacturer in North Carolina to expand capacity.
• As of December 31, 2025, InspireMD had $8.9 million in cash and equivalents and $45.3 million in short-term investments, with a current ratio of 5.74 and cash ratio of 5.06, indicating strong liquidity.
• For the fiscal year ended December 31, 2025, the company reported a net loss of $48.8 million and basic and diluted EPS of -$0.76.
• Management has expressed substantial doubt about the company’s ability to continue as a going concern due to recurring losses and negative cash flows.
• The company has limited experience selling, marketing, and distributing products in the U.S. and is building out its direct sales organization and distribution capabilities to support commercialization of CGuard Prime.
• Risks include challenges in recruiting and retaining sales and manufacturing personnel, achieving market acceptance, pricing and reimbursement uncertainties, geopolitical risks related to operations in Israel, and the need to raise additional capital to fund operations and growth.
• Recent news reports indicate Q4 revenue growth and guidance for 65% revenue growth in 2026, alongside continued net losses reported for Q4 and full year 2025.
• The company appointed a new Chief Medical Officer in November 2025 and launched CGuard Prime in the U.S. in July 2025.